Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Blinatumomab for the treatment of B-cell lymphoma
Eunhye Oak
,
Nancy L. Bartlett
Section of Medical Oncology
Siteman Cancer Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
36
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Blinatumomab for the treatment of B-cell lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
B-cell Lymphoma
100%
Blinatumomab
100%
Bispecific T-cell Engager (BiTE)
42%
Precursor B-cell Acute Lymphoblastic Leukemia
42%
Tumor
14%
Clinical Trials
14%
Lymphoma Patients
14%
B Cells
14%
Targeted Therapy
14%
Costimulation
14%
Phase II Study
14%
Cytotoxic T Cells
14%
Bispecific Antibody
14%
Non-Hodgkin Lymphoma
14%
B-cell non-Hodgkin Lymphoma (B-NHL)
14%
Expert Opinion
14%
Indolent Lymphoma
14%
T-cell Mediated
14%
Continuous Infusion
14%
Unmet Medical Need
14%
Pharmacology
14%
Infusion Therapy
14%
Area Cover
14%
Relapsed Lymphoma
14%
Large Trials
14%
MHC Class I Antigen Presentation
14%
Tissue Penetration
14%
CD3 Antigen
14%
Aggressive non-Hodgkin Lymphoma
14%
Oral Agents
14%
Aggressive Histology
14%
CD19 Antigen
14%
Medicine and Dentistry
B-Cell Lymphoma
100%
Blinatumomab
100%
T Cell
57%
Non-Hodgkin Lymphoma
57%
Precursor
42%
Acute Lymphoblastic Leukemia
42%
B Cell
28%
Neoplasm
14%
Clinical Trial
14%
Cancer
14%
Targeted Therapy
14%
Bispecific Antibody
14%
Cytotoxic T-Cell
14%
Continuous Infusion
14%
CD3 Antigen
14%
CD19 Antigen
14%
Infusion Therapy
14%
Diseases
14%
Oral
14%
Pharmacology, Toxicology and Pharmaceutical Science
B Cell Lymphoma
100%
Blinatumomab
100%
Nonhodgkin Lymphoma
57%
Acute Lymphoblastic Leukemia
42%
Neoplasm
14%
Clinical Trial
14%
Bispecific Antibody
14%
CD19 Antigen
14%
Preclinical Pharmacology
14%
CD3 Antigen
14%
Diseases
14%